Randomised trials of Graft versus Host Disease prophylaxis in haemopoietic stem cell transplantation.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Reviews on recent clinical trials

• Publication date

  2008-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/157488708784223790PMID 18474024
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expanding the role of umbilical cord blood transplantation

  2007cited by this paper
• Chronic graft‐versus‐host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program

  2007cited by this paper
• Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.

  2007cited by this paper
• Advances in the understanding of acute graft‐versus‐host disease

  2007cited by this paper
• Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation

  2006cited by this paper
• Extending Postgrafting Cyclosporine Decreases the Risk of Severe Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation

  2006cited by this paper
• Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study.

  2006cited by this paper
• Chronic graft versus host disease

  2006cited by this paper
• Chronic graft-versus-host disease

  2006cited by this paper
• Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease

  2006cited by this paper
• Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients

  2006cited by this paper
• Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.

  2006cited by this paper
• High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT.

  2006cited by this paper
• Graft-versus-host disease after allogeneic stem cell transplantation: evolving concepts and novel therapies including photopheresis.

  2006cited by this paper
• The initial phase of graft-versus-host disease is associated with a decrease of CD4+CD25+ regulatory T cells in the peripheral blood of patients after allogeneic stem cell transplantation.

  2006cited by this paper
• Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath ‘in the bag’ as T-cell depletion: the Leiden experience

  2006cited by this paper
• Optimizing the use of cyclosporin in allogeneic stem cell transplantation

  2006cited by this paper
• Human Regulatory T Cells Control Xenogeneic Graft-versus-Host Disease Induced by Autologous T Cells in RAG2−/−γc−/− Immunodeficient Mice

  2006cited by this paper
• Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).

  2006cited by this paper
• Suppressor Function of Umbilical Cord Blood-Derived CD4+CD25+ T-Regulatory Cells Exposed to Graft-versus-Host Disease Drugs

  2006cited by this paper
• Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production.

  2006cited by this paper
• Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD.

  2006cited by this paper
• Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation.

  2006cited by this paper
• Human mesenchymal stem cells modulate allogeneic immune cell responses.

  2005cited by this paper
• Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings

  2005cited by this paper
• Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.

  2005cited by this paper
• Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease.

  2005cited by this paper
• CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens

  2005cited by this paper
• New approaches for preventing and treating chronic graft-versus-host disease.

  2005cited by this paper
• Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation.

  2005cited by this paper
• Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation.

  2005cited by this paper
• Haemopoietic stem cell transplantation in Australia and New Zealand, 1992–2001: progress report from the Australasian Bone Marrow Transplant Recipient Registry

  2005cited by this paper
• Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial.

  2005cited by this paper
• Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials.

  2005cited by this paper
• A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.

  2005cited by this paper
• Selective depletion strategies in allogeneic stem cell transplantation.

  2005cited by this paper
• Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 Trial.

  2004cited by this paper
• A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.

  2004cited by this paper
• Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies

  2004cited by this paper
• Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

  2004cited by this paper
• A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation

  2004cited by this paper
• Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome.

  2004cited by this paper
• Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.

  2004cited by this paper
• Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.

  2004cited by this paper
• Should Immunoglobulin Therapy Be Used in Allogeneic Stem-Cell Transplantation?

  2003cited by this paper
• CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation

  2003cited by this paper
• Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.

  2003cited by this paper
• Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation.

  2003cited by this paper
• Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation.

  2002cited by this paper
• The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors.

  2002cited by this paper
• A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation

  2002cited by this paper
• Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study.

  2002cited by this paper
• Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease.

  2002cited by this paper
• Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation.

  2002cited by this paper
• Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation

  2002cited by this paper
• Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation

  2001cited by this paper
• Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.

  2001cited by this paper
• Increased risk of leukemia relapse with high dose cyclosporine after allogeneic marrow transplantation for acute leukemia: 10 year follow-up of a randomized study.

  2001cited by this paper
• Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial.

  2001cited by this paper
• Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).

  2001cited by this paper
• Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.

  2000cited by this paper
• Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial.

  2000cited by this paper
• Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial.

  2000cited by this paper
• T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities.

  2000cited by this paper
• Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study.

  2000cited by this paper
• Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry.

  1999cited by this paper
• Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospect

  1999cited by this paper
• Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.

  1998cited by this paper
• Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: a randomized study of low-dose cyclosporin versus low-dose cyclosporin and low-dose methotrexate.

  1998cited by this paper
• Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease.

  1998cited by this paper
• A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT)

  1997cited by this paper
• The Immunopathophysiology of Acute Graft‐Versus‐Host‐Disease

  1996cited by this paper
• Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.

  1993cited by this paper
• Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia.

  1991cited by this paper
• What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?

  1990cited by this paper
• Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial.

  1989cited by this paper
• High incidence of early leukemic relapse in patients given cyclosporin and T cell depleted HLA-identical sibling marrow transplants for acute leukemia in first remission.

  1988cited by this paper
• Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.

  1986cited by this paper
• Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients.

  1984cited by this paper
• METHOTREXATE REGIMENS FOR CONTROL OF GRAFT-VERSUS-HOST DISEASE IN DOGS WITH ALLOGENEIC MARROW GRAFTS

  1970cited by this paper

• Analysis of the variable factors affecting changes in the blood concentration of cyclosporine before and after transfusion of red blood cell concentrate

  2022cites this paper
• Single and multiple dose MultiStem (multipotent adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation: a phase 1 trial.

  2015cites this paper
• Oral cyclosporine A treatment is feasible after myeloablative conditioning in allogeneic hematopoietic stem cell transplantation

  2015cites this paper
• Evaluation of the physicochemical compatibility of cyclosporin infusion and parenteral nutrition when intravenously administered via the same central line lumen

  2015cites this paper
• Graft Versus Host Disease: From Basics to the Clinic

  2014cites this paper
• IMMUNE REPERTOIRE DIVERSITY IN ALLOGENEIC STEM CELL TRANSPLANTATION AND ITS IMPLICATIONS FOR INFECTIONS AND THE GRAFT VERSUS LEUKEMIA EFFECT

  2014cites this paper
• Clinical pharmacogenetics of methotrexate.

  2011cites this paper
• Insufficient evidence for association of NOD2/CARD15 or other inflammatory bowel disease-associated markers on GVHD incidence or other adverse outcomes in T-replete, unrelated donor transplantation.

  2010cites this paper
• Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators.

  2009cites this paper